Case Discussion “Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: analysis of risk factors including the 70-gene signature”

Chairs: Naoki Niikura (Tokai University)
Hiroshi Takeyama (The Jikei University, School of Medicine)

Plenary Lecture-2 “Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: analysis of risk factors including the 70-gene signature”
Emiel J. Rutgers (Netherlands Cancer Institute)

Opening Remarks

Symposium 1
“Radiotherapy: Consensus and future perspectives”

Chairs: John R. Benson (University of Cambridge)
Michio Yoshimura (Kyoto University)

“Hypofractionated radiotherapy for women with early breast cancer is safe, effective and convenient”
John Yarnold (The Institute of Cancer Research & Royal Marsden NHS Foundation Trust)

“The current status and future of radiation treatment strategy in Japan”
Michio Yoshimura (Kyoto University)

“Breast conserving therapy: when can radiotherapy be omitted?”
Reshma Jagsi (University of Michigan)

Symposium 2 “DCIS”

Chairs: Chiun Sheng Huang (National Taiwan University)
Bruce Mann (the University of Melbourne)

“Paradigm Shift Toward Reducing Overtreatment of Ductal Carcinoma in Situ of Breast”
Yasuaki Sagara (Hakuaikai Social Medical Cooperation /Kyoto University Hospital /Brigham and Women’s Hospital)

“Treatment of Low Risk DCIS”
John R. Benson (University of Cambridge)

Diagnosis of DCIS
Woo Kyung Moon (Seoul National University)
Invited Lecture “Microenvironment Determines Therapeutic Response of Primary Tumor and Metastases”

Chair: Yoshinori Ito (Cancer Institute Hospital)
Rakesh K. Jain (Radiation Oncology (Tumor Biology), Harvard Medical School, Boston, Massachusetts, USA / Edwin L. Steele Laboratories, Massachusetts General Hospital, Boston, Massachusetts, USA)

Luncheon Seminar 26

“Controversies in the current management of DCIS”
Chair: Shigeru Imoto (Department of Breast Surgery, School of Medicine Kyorin University)
Alastair M. Thompson (Department of Breast Surgical Oncology and Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, USA)

Kyoto International Conference Center 1F Main Hall

Management of Axilla: Issue and future perspectives

Chair: Emiel Rutgers (Netherlands Cancer Institute)

Plenary Lecture-1 Management of Axilla: Issue and future perspectives
Ismail Jatoi (University of Texas Health Center, San Antonio)

ER+ disease and late recurrence

Chair: Nadia Harbeck (Ludwig-Maximilians-University of Munich)

Plenary Lecture-2 ER+ disease and late recurrence
Eric Winer (Dana-Farber Cancer Institute, Harvard Medical School)

Management of multiple ipsilateral breast cancers

Chair: Seigo Nakamura (Showa University School of Medicine)

Plenary Lecture-3 Management of multiple ipsilateral breast cancers
John Benson (University of Cambridge)

Plenary Lecture-4 Neoadjuvant therapy of triple negative cancer
(Video)
Virginia Kaklamani (University of Texas Health Science Center San Antonio)
Kyoto International Conference Center  1F Annex Hall 1

Sponsored Symposium 1
Local management of Clinical Complete Response after neoadjuvant therapy

15:30-17:00

Chairs: Giuseppe Curigliano (Istituto Europeo di Oncologia and University of Milano Early Drug Development)
Alastair Thompson (University of Texas M.D. Anderson Cancer Center)

Imaging
Masako Kataoka (Kyoto University Hospital)

Surgery
Wonshik Han (Seoul National University College of Medicine)

Radiotherapy
Reshma Jagsi (University of Michigan)

Marking of the lesion
Naoki Hayashi (St. Luke’s International Hospital)

Algorithm and prediction
Masahiro Takada (Kyoto University Hospital)

Kyoto International Conference Center  1F Annex Hall 2

Case Discussion “Risk reduction surgery”

15:30-16:30

Chairs: Bruce Mann (The University of Melbourne)
Shinji Ohno (Cancer Institute Hospital of the JFCR)

Speaker: Stephen Grobmyer (Cleveland Clinic)
Speaker: Ava Kwong (University of Hong Kong)
Discussant: Yasuaki Sagara (Hakuaikai Social Cooperation)
Hiroko Bando (University of Tsukuba)

19-May Saturday

Kyoto International Conference Center  1F Annex Hall

Sponsored Symposium 2
Indication of neoadjuvant Therapy

8:00-9:00

Chairs: Naoki Niikura (Department of Breast and Endocrine Surgery, Tokai University School of Medicine)
Shigehira Saji (Department of Medical Oncology, Fukushima Medical University)

Neoadjuvant for luminal type
Speaker: Takayuki Ueno (Breast Surgical Oncology, The Cancer Institute Hospital of JFCR)

Neoadjuvant for HER2 positive, Triple Negative
Speaker: Nicholas C. Turner (Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research and Royal Marsden Hospital, UK)

Surgical management after neoadjuvant therapy
Speaker: Alastair M. Thompson (Department of Breast Surgical Oncology and Department of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, USA)

Sponsored by Pfizer Japan Inc.
Consensus Session-1

Chairs: Eric Winer (Dana-Farber Cancer Institute, Harvard Medical School)
John R. Benson (University of Cambridge)
Reshma Jagsi (University of Michigan)
Masakazu Toi (Kyoto University)
Takashi Inamoto (Tenri Health Care University)
Chikako Yamauchi (Shiga General Hospital)

Break Time & Photo

Consensus Session-2

Closing Remarks

Kyoto International Conference Center  2F Room B-2

Prefered Abstracts Oral presentation

Chair: Nobuhiko Shinkura (Sawai Memorial Breast Clinic)

PO-1  Ex vivo expansion of breast circulating tumor cells predicts patient responses to therapy
Govind Babu kanakasetty (Dept.of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India)

PO-2  Prospectively patient-reported outcome measures in breast cancer patients treated for lateradiation-induced tissue toxicity by hyperbaric oxygen therapy, 6 months follow-up
David N Teguh (Department of Surgery/Hyperbaric Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands)

PO-3  MRI findings of low grade DCIS
Masako Kataoka (Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine)

PO-4  Molecular Imaging Heterogeneity Study of breast tumors as a new diagnostic parameter.
Michel Herranz (Molecular Oncology and Imaging Program, ERGAS-GALARIA)
## Surgical Oncology

### Poster Discussion

**Poster** | **11:00-11:20**
--- | ---
**PP-1** | Surgical impact on stage IV breast cancer  
Wakako Tsuji (Department of Breast Surgery, Shiga General Hospital)  
**PP-2** | Infection associated with immediate breast reconstruction after mastectomy  
Hiroki Ito (Department of Breast Surgery, Kaneko clinic, Japan)  
**PP-3** | Prevention of seroma formation after modified radical mastectomy in breast cancer by dead space closure technique: Prospective randomized control trial  
Satchachon Changthom (Mahasarakham Hospital)  
**PP-4** | A case of recurrent stromal sarcoma of the breast  
Reiko Sato (Department of Surgery, Komatsu Municipal Hospital)  
**PP-5** | withdrawn  
**PP-6** | withdrawn  
**PP-7** | Axillary recurrence after negative sentinel lymph node biopsy using Indocyanine green fluorescence method for breast cancer from the KBCRN multicenter cohort study  
Yurina Maeshima (Department of Breast Surgery Tazuke kofukai Foundation, Medical Research Institute)  
**PP-8** | Application of robotic surgery (da Vinci) in the management of breast cancer- preliminary results and experience sharing.  
Hung-Wen Lai (Changhua Christian Hospital)  
**PP-9** | withdrawn  
**PP-10** | Attention to local recurrences as subcutaneous tumors after skin-sparing mastectomy or nipple-sparing mastectomy with immediate breast reconstruction  
Hajime Matsumoto (Department of Breast Surgery, Shinko Hospital, Hyogo, Japan)  

## Radiation Oncology

### Poster Discussion

**Poster** | **11:00-11:20**
--- | ---
**PP-11** | withdrawn  
**PP-12** | Pentagamaboronon-0-sorbitol induces cell death and inhibits migration against HER2-overexpressed breast cancer cells  
Lailatul Qodria (Master student of Biotechnology Study Programe, Graduate School, Universitas Gadjah Mada, Teknika Utara Yogyakarta 55281, Indonesia)  
**PP-13** | pentagamaboronon-0 fructose complex (PGB-0-F) performs cytotoxic effect and anti-metastatic activity toward MCF-7/HER2 cells  
Indah Hairunisa (Master Student of Biotechnology Study Program, Graduate School, Universitas Gadjah Mada, Teknika Utara, Pogung, Mlati, Sleman, Yogyakarta, 55281, Indonesia.)
<table>
<thead>
<tr>
<th>PP-14</th>
<th>Investigations of dosimetric Evaluation and cytotoxicity of boron compounds for application of boron neutron capture therapy to recurrent breast cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hironobu Yanagie (Research Institute of Healthy Living, Niigata University of Pharmacy and Applied Life Sciences)</td>
</tr>
<tr>
<td>PP-15</td>
<td>Assessment of access to digital resources (smart phone and cross-platform instant messaging) of breast cancer patients in developing countries</td>
</tr>
<tr>
<td></td>
<td>Ramaiah Vinay. Kumar (Department of Radiation Oncology, Kidwai Memorial Institute of Oncology)</td>
</tr>
<tr>
<td>PP-16</td>
<td>Prospectively patient-reported outcome measures in breast cancer patients treated for late radiation-induced tissue toxicity by hyperbaric oxygen therapy, 6 months follow-up</td>
</tr>
<tr>
<td></td>
<td>David N. Teguh (Department of Surgery/Hyperbaric Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands)</td>
</tr>
</tbody>
</table>

### Medical Oncology Poster Discussion

<table>
<thead>
<tr>
<th>Poster</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PP-17</td>
<td>11:00-11:20</td>
</tr>
</tbody>
</table>

**PP-17** Boron-containing pharmaceutical pentagamaboronon-0 complex with polyol sugar sorbitol potency as anticancer agent through the inhibition of breast cancer cell proliferation and migration

- Ratna Dwi. Ramadani (Master student of Biotechnology Study Program, Graduate School, Universitas Gadjah Mada, Yogyakarta, Indonesia)
- Yogi Ertanto (Master Student of Biotechnology Study Program, Graduate School, Universitas Gadjah Mada, Teknika Utara, Pogung, Sleman, Yogyakarta, 55281, Indonesia)
- Masaki Hirabatake (Department of Pharmacy, Kobe City Medical Center General Hospital, Japan)
- Akemi Kataoka (Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan)
- Hiroyuki Maeda (First department of Surgery, Faculty of Medicine, University of Fukui)
- Michiko Kurikawa (Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan)

### Pathology Poster Discussion

<table>
<thead>
<tr>
<th>Poster</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PP-24</td>
<td>11:00-11:20</td>
</tr>
</tbody>
</table>

**PP-24** Number of negative lymph nodes is potential prognostic factor in breast cancer in Thailand.

- Tanin Titipungul (Anatomical pathology)
- Tingting Feng (Department of Surgery, Ng Teng Fong General Hospital, Singapore)
- Putachart Misang (Department of anatomical pathology, Hatyai hospital, Songkhla, Thailand)
PP-27
withdrawn

**Biology Poster Discussion**

PP-28
*Ex vivo* expansion of breast circulating tumor cells predicts patient responses to therapy
Govind Babu kanakasetty (Dept.of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India)

PP-29
Wnt5a accelerates aggressiveness of ER-positive breast cancer by promoting cancer cell migration through ALCAM pathway
Yosie Kobayashi (Department of Surgical Oncology, Research Center for Radiation Casualty Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan)

PP-30
Shedding light to shedding HER2-ECD
Noriko Miwa (Department of Breast Surgical Oncology, Nishiwaki Municipal Hospital, Hyogo)

PP-31
Proliferation and migration inhibitory effects of genistein on CHO-K1, Ovarium cells and 4T1, breast cancer cells occur through cell cycle arrest, suppression of MMP-9 and RAC-1 protein expression
Edy Meiyanto (University of Gadjah Mada)

PP-32
Age Impact as a Prognostic Factor in Luminal, HER2 and triple-negative breast cancer.
Hung Chun Skye. Cheng (Department of Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center)

PP-33
Expression of PgRMC1 (Progesterone Receptor Membrane component 1) in breast cancer
Manami Tada (Department of Breast Surgery, School of medicine, Kyorin university hospital, Tokyo, Japan)

**Epidemiology Poster Discussion**

PP-34
Risk factors for delay in presentation of breast cancer: a real-word evidence from northeast of China
Jia Wang (Department of Breast Surgery, Institute of Breast Disease, 2nd Hospital of Dalian Medical University)

PP-35
withdrawn

PP-36
Characteristics of molecular breast cancer subtypes among Uzbekistan’s women
Gulya Miryusupova (Breast cancer surgery department)

PP-37
The clinicopathological features of young Japanese women (≤35 years old) with hormone receptor-positive breast cancer who became pregnant after treatment
Tomomi Abe (Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research)

PP-38
HBOC pre-counseling by medical oncologist is important opportunity to increase genetic counseling and BRCA testing
Takahiro Kogawa (Breast Medical Oncology, National Cancer Center Hospital East, Kashiwa)

**Imaging Radiation Poster Discussion**

PP-39
MRI findings of low grade DCIS
Masako Kataoka (Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital)

PP-40
withdrawn
<table>
<thead>
<tr>
<th>PP-41</th>
<th>Second-look US using Real-time Virtual Sonography increases the sonographic detection rate of MRI-detected lesions with non-mass enhancement on breast MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>a90074</td>
<td>Shogo Nakano (Division of Breast and Endocrine Surgery, Department of Surgery, Aichi Medical University, Aichi, Japan)</td>
</tr>
<tr>
<td>PP-42</td>
<td>Importance of detection of intratumoral heterogeneity on diffusion-weighted and T2-weighted MRI for predicting breast cancer subtypes</td>
</tr>
<tr>
<td>a90077</td>
<td>Sachiko Yuen (Breast Research Center, The Shinko Institute for Medical Research, Shinko Hospital, Kobe, Japan)</td>
</tr>
<tr>
<td>PP-43</td>
<td>Importance of teamwork for performing scalp cooling: an experience from the PAX-15 study</td>
</tr>
<tr>
<td>a10001</td>
<td>Makiko Higuchi (Kanazawa University Hospital Innovative Clinical Research Center)</td>
</tr>
<tr>
<td>PP-44</td>
<td>Dedicated breast PET (dbPET) for quantifies response to neoadjuvant therapy in breast cancer.</td>
</tr>
<tr>
<td>a10002</td>
<td>Herranz Michel (Molecular Oncology and Imaging Program SERGAS-GALARIA / Molecular Breast Imaging Division SERGAS-GALARIA)</td>
</tr>
<tr>
<td>PP-45</td>
<td>Molecular Imaging Heterogeneity Study of breast tumors as a new diagnostic parameter.</td>
</tr>
<tr>
<td>a10003</td>
<td>Herranz Michel (Molecular Oncology and Imaging Program SERGAS-GALARIA / Molecular Breast Imaging Division SERGAS-GALARIA)</td>
</tr>
<tr>
<td>PP-46</td>
<td>Design, development and validation of the first 3D PET manual breast guided biopsy system.</td>
</tr>
<tr>
<td>a10004</td>
<td>Herranz Michel (Molecular Oncology and Imaging Program SERGAS-GALARIA / Molecular Breast Imaging Division SERGAS-GALARIA)</td>
</tr>
<tr>
<td>PP-47</td>
<td>Breast MRI and dedicated breast PET (dbPET): Synergies and multimodal imaging.</td>
</tr>
<tr>
<td>a10005</td>
<td>Herranz Michel (Molecular Oncology and Imaging Program SERGAS-GALARIA / Molecular Breast Imaging Division SERGAS-GALARIA)</td>
</tr>
</tbody>
</table>